{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T01:13:40Z","timestamp":1778807620110,"version":"3.51.4"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.bbrc.2024.150424","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T19:00:03Z","timestamp":1721329203000},"page":"150424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Mechanism of epigallocatechin gallate in treating non-alcoholic fatty liver disease: Insights from network pharmacology and experimental validation"],"prefix":"10.1016","volume":"734","author":[{"given":"Danting","family":"Mao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaojiao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziren","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.bbrc.2024.150424_bib1","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrgastro.2013.183","article-title":"NAFLD, NASH and liver cancer","volume":"10","author":"Michelotti","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.bbrc.2024.150424_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.bbrc.2024.150424_bib3","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3350\/cmh.2022.0239","article-title":"Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach","volume":"28","author":"Le","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"issue":"12","key":"10.1016\/j.bbrc.2024.150424_bib4","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.tem.2019.08.006","article-title":"Emerging molecular targets for treatment of nonalcoholic fatty liver disease","volume":"30","author":"Chen","year":"2019","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.bbrc.2024.150424_bib5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-pathol-020117-043617","article-title":"Recent insights into the pathogenesis of nonalcoholic fatty liver disease","volume":"13","author":"Arab","year":"2018","journal-title":"Annu. Rev. Pathol."},{"issue":"10290","key":"10.1016\/j.bbrc.2024.150424_bib6","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bbrc.2024.150424_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.clinre.2021.101710","article-title":"Pathogenetic mechanisms of nonalcoholic fatty liver disease and inhibition of the inflammasome as a new therapeutic target","volume":"45","author":"Colak","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"9","key":"10.1016\/j.bbrc.2024.150424_bib8","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/s41423-021-00740-6","article-title":"NLRP3 inflammasome activation and cell death","volume":"18","author":"Huang","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"8","key":"10.1016\/j.bbrc.2024.150424_bib9","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.7150\/ijbs.81017","article-title":"A lipid perspective on regulated pyroptosis","volume":"19","author":"Qiu","year":"2023","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bbrc.2024.150424_bib10","first-page":"1","article-title":"Deficiency of the purinergic receptor 2X(7) attenuates nonalcoholic steatohepatitis induced by high-fat diet: possible role of the NLRP3 inflammasome","volume":"8962458","author":"Blasetti Fantauzzi","year":"2017","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"3","key":"10.1016\/j.bbrc.2024.150424_bib11","first-page":"20","article-title":"Salubrious effects of green tea catechins on fatty liver disease: a systematic review","volume":"9","author":"Abunofal","year":"2022","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.bbrc.2024.150424_bib12","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.foodchem.2022.132135","article-title":"Epigallocatechin 3-gallate: from green tea to cancer therapeutics","volume":"379","author":"Alam","year":"2022","journal-title":"Food Chem."},{"issue":"1","key":"10.1016\/j.bbrc.2024.150424_bib13","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s40168-021-01115-9","article-title":"Gut microbiota from green tea polyphenol-dosed mice improves intestinal epithelial homeostasis and ameliorates experimental colitis","volume":"9","author":"Wu","year":"2021","journal-title":"Microbiome"},{"key":"10.1016\/j.bbrc.2024.150424_bib14","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ijbiomac.2022.03.004","article-title":"Role of polyphenols in combating Type 2 Diabetes and insulin resistance","volume":"206","author":"Shahwan","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bbrc.2024.150424_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejphar.2014.09.046","article-title":"Quercetin, luteolin and epigallocatechin gallate alleviate TXNIP and NLRP3-mediated inflammation and apoptosis with regulation of AMPK in endothelial cells","volume":"745","author":"Wu","year":"2014","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bbrc.2024.150424_bib16","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3390\/nu13020599","article-title":"Epigallocatechin-3-Gallate dampens non-alcoholic fatty liver by modulating liver function, lipid profile and macrophage polarization","volume":"13","author":"Du","year":"2021","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.bbrc.2024.150424_bib17","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3164\/jcbn.20-39","article-title":"Epigallocatechin-3-gallate (EGCG) attenuates non-alcoholic fatty liver disease via modulating the interaction between gut microbiota and bile acids","volume":"67","author":"Naito","year":"2020","journal-title":"J. Clin. Biochem. Nutr."},{"issue":"30","key":"10.1016\/j.bbrc.2024.150424_bib18","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.2174\/1568026616666160530181328","article-title":"Drug repositioning through network pharmacology","volume":"16","author":"Ye","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"issue":"5","key":"10.1016\/j.bbrc.2024.150424_bib19","first-page":"323","article-title":"Network pharmacology approaches for research of Traditional Chinese Medicines","volume":"21","author":"Li","year":"2023","journal-title":"Chin. J. Nat. Med."},{"issue":"9","key":"10.1016\/j.bbrc.2024.150424_bib20","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.bbrc.2024.150424_bib21","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bbrc.2024.150424_bib22","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hep.29721","article-title":"Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis","volume":"68","author":"Younossi","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bbrc.2024.150424_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biom12060824","article-title":"NAFLD: mechanisms, treatments, and biomarkers","volume":"12","author":"Nassir","year":"2022","journal-title":"Biomolecules"},{"issue":"27","key":"10.1016\/j.bbrc.2024.150424_bib24","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.3748\/wjg.v24.i27.2974","article-title":"Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from \"two hit theory\" to \"multiple hit model\u201d","volume":"24","author":"Fang","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbrc.2024.150424_bib25","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1146\/annurev-pathmechdis-032521-102529","article-title":"Role of the inflammasome in liver disease","volume":"17","author":"De Carvalho Ribeiro","year":"2022","journal-title":"Annu. Rev. Pathol."},{"issue":"8","key":"10.1016\/j.bbrc.2024.150424_bib26","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.tips.2022.04.003","article-title":"NLRP3 and pyroptosis blockers for treating inflammatory diseases","volume":"43","author":"Coll","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.bbrc.2024.150424_bib27","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s10571-022-01250-3","article-title":"Role of pyroptosis, a pro-inflammatory programmed cell death, in epilepsy","volume":"43","author":"Atabaki","year":"2023","journal-title":"Cell. Mol. Neurobiol."},{"issue":"9","key":"10.1016\/j.bbrc.2024.150424_bib28","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.7150\/thno.71086","article-title":"Pyroptosis in inflammatory diseases and cancer","volume":"12","author":"Rao","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.bbrc.2024.150424_bib29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fnint.2020.00037","article-title":"Key mechanisms and potential targets of the NLRP3 inflammasome in neurodegenerative diseases","volume":"14","author":"Guan","year":"2020","journal-title":"Front. Integr. Neurosci."},{"issue":"5","key":"10.1016\/j.bbrc.2024.150424_bib30","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.cell.2020.02.002","article-title":"Structural mechanism for GSDMD targeting by autoprocessed caspases in pyroptosis","volume":"180","author":"Wang","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bbrc.2024.150424_bib31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41418-018-0212-6","article-title":"Pyroptosis versus necroptosis: similarities, differences, and crosstalk","volume":"26","author":"Frank","year":"2019","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.bbrc.2024.150424_bib32","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1080\/13880209.2022.2029501","article-title":"Jinlida granules ameliorate the high-fat-diet induced liver injury in mice by antagonising hepatocytes pyroptosis","volume":"60","author":"Hao","year":"2022","journal-title":"Pharm. Biol."},{"issue":"4","key":"10.1016\/j.bbrc.2024.150424_bib33","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jhep.2017.11.040","article-title":"Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice","volume":"68","author":"Xu","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2024.150424_bib34","doi-asserted-by":"crossref","first-page":"155111","DOI":"10.1016\/j.phymed.2023.155111","article-title":"Xie Zhuo Tiao Zhi formula modulates intestinal microbiota and liver purine metabolism to suppress hepatic steatosis and pyroptosis in NAFLD therapy","volume":"121","author":"Qiu","year":"2023","journal-title":"Phytomedicine"},{"issue":"2","key":"10.1016\/j.bbrc.2024.150424_bib35","doi-asserted-by":"crossref","first-page":"117239","DOI":"10.1016\/j.jep.2023.117239","article-title":"Calenduloside E ameliorates non-alcoholic fatty liver disease via modulating a pyroptosis-dependent pathway","volume":"319","author":"Le","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.bbrc.2024.150424_bib36","first-page":"896","article-title":"Plant-derived bioactive compounds regulate the NLRP3 inflammasome to treat NAFLD","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbrc.2024.150424_bib37","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2147\/DDDT.S180079","article-title":"Epigallocatechin-3-gallate in the prevention and treatment of hepatocellular carcinoma: experimental findings and translational perspectives","volume":"13","author":"Bimonte","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"issue":"11","key":"10.1016\/j.bbrc.2024.150424_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu10111754","article-title":"Protective effects of five structurally diverse flavonoid subgroups against chronic alcohol-induced hepatic damage in a mouse model","volume":"10","author":"Zhao","year":"2018","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.bbrc.2024.150424_bib39","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/ptr.7383","article-title":"Costunolide protects against alcohol-induced liver injury by regulating gut microbiota, oxidative stress and attenuating inflammation in vivo and in vitro","volume":"36","author":"Mao","year":"2022","journal-title":"Phytother Res."},{"issue":"4","key":"10.1016\/j.bbrc.2024.150424_bib40","first-page":"483","article-title":"Epigallocatechin-3-gallate alleviates type 2 diabetes mellitus via beta-cell function improvement and insulin resistance reduction","volume":"25","author":"Zhu","year":"2022","journal-title":"Iran J Basic Med Sci"},{"issue":"3","key":"10.1016\/j.bbrc.2024.150424_bib41","first-page":"1","article-title":"Salubrious effects of green tea catechins on fatty liver disease: a systematic review","volume":"9","author":"Abunofal","year":"2022","journal-title":"Medicine (Baltim.)"},{"issue":"1","key":"10.1016\/j.bbrc.2024.150424_bib42","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13020-023-00856-z","article-title":"Epigallocatechin gallate prevents cardiomyocytes from pyroptosis through lncRNA MEG3\/TAF15\/AIM2 axis in myocardial infarction","volume":"18","author":"Qin","year":"2023","journal-title":"Chin. Med."},{"issue":"1","key":"10.1016\/j.bbrc.2024.150424_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/tnsci-2022-0326","article-title":"EGCG promotes the sensory function recovery in rats after dorsal root crush injury by upregulating KAT6A and inhibiting pyroptosis","volume":"14","author":"Wang","year":"2023","journal-title":"Transl. Neurosci."},{"issue":"1","key":"10.1016\/j.bbrc.2024.150424_bib44","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12943-023-01790-2","article-title":"Metal-enriched HSP90 nanoinhibitor overcomes heat resistance in hyperthermic intraperitoneal chemotherapy used for peritoneal metastases","volume":"22","author":"Wang","year":"2023","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.bbrc.2024.150424_bib45","first-page":"665","article-title":"EGCG reduces hepatocyte apoptosis and the expression of endoplasmic reticulum stress proteins perk and GRP78 in type 2 diabetic rats","volume":"47","author":"Luo","year":"2020","journal-title":"tea communication"},{"key":"10.1016\/j.bbrc.2024.150424_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/5538643","article-title":"A network pharmacology and molecular docking strategy to explore potential targets and mechanisms underlying the effect of curcumin on osteonecrosis of the femoral head in systemic lupus erythematosus","volume":"2021","author":"Kang","year":"2021","journal-title":"BioMed Res. Int."},{"issue":"1","key":"10.1016\/j.bbrc.2024.150424_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ddr.22150","article-title":"Costunolide attenuates high-fat diet-induced inflammation and oxidative stress in non-alcoholic fatty liver disease","volume":"85","author":"Wang","year":"2024","journal-title":"Drug Dev. Res."},{"issue":"3","key":"10.1016\/j.bbrc.2024.150424_bib48","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1080\/21655979.2022.2037374","article-title":"Hepatoprotective mechanism of Silybum marianum on nonalcoholic fatty liver disease based on network pharmacology and experimental verification","volume":"13","author":"Jiang","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.bbrc.2024.150424_bib49","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jconrel.2023.01.039","article-title":"Albumin-fused long-acting FGF21 analogue for the treatment of non-alcoholic fatty liver disease","volume":"355","author":"Chikamatsu","year":"2023","journal-title":"J. Contr. Release : official journal of the Controlled Release Society"},{"issue":"6","key":"10.1016\/j.bbrc.2024.150424_bib50","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","article-title":"MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition","volume":"15","author":"Coll","year":"2019","journal-title":"Nat. Chem. Biol."},{"issue":"2","key":"10.1016\/j.bbrc.2024.150424_bib51","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1124\/jpet.123.001639","article-title":"Pharmacology of a potent and novel inhibitor of the NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome that attenuates development of nonalcoholic steatohepatitis and liver fibrosis","volume":"386","author":"Povero","year":"2023","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"6","key":"10.1016\/j.bbrc.2024.150424_bib52","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41374-018-0177-6","article-title":"Impaired mitophagy triggers NLRP3 inflammasome activation during the progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis","volume":"99","author":"Zhang","year":"2019","journal-title":"Lab. Invest."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X24009604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X24009604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T19:31:12Z","timestamp":1732649472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X24009604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":52,"alternative-id":["S0006291X24009604"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2024.150424","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanism of epigallocatechin gallate in treating non-alcoholic fatty liver disease: Insights from network pharmacology and experimental validation","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2024.150424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"150424"}}